InVitro International (IVRO)
USD 0.07
(-6.49%)
USD 0.07
(-6.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6680.00 USD | 80.54% |
| 2022 | 16.45 Thousand USD | -368.77% |
| 2021 | 108.21 Thousand USD | -169.06% |
| 2020 | 65.02 Thousand USD | -50.46% |
| 2019 | 91.29 Thousand USD | 24.45% |
| 2018 | 72.82 Thousand USD | 2.99% |
| 2017 | 65.65 Thousand USD | -56.47% |
| 2016 | 136.85 Thousand USD | -48.47% |
| 2015 | 250.87 Thousand USD | 708.01% |
| 2014 | 30.3 Thousand USD | 0.0% |
| 1996 | -1.9 Million USD | 36.67% |
| 1995 | -3 Million USD | 33.33% |
| 1994 | -4.5 Million USD | -36.36% |
| 1993 | -3.3 Million USD | 37.74% |
| 1992 | -5.1 Million USD | -65.63% |
| 1991 | -3.2 Million USD | -1700.0% |
| 1990 | 200 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 9650.00 USD | -62.58% |
| 2024 Q2 | 39.29 Thousand USD | 160.73% |
| 2024 Q3 | 7940.00 USD | -63.72% |
| 2023 Q2 | -14.35 Thousand USD | 52.34% |
| 2023 Q4 | 41.64 Thousand USD | 329.17% |
| 2023 Q1 | -30.11 Thousand USD | 65.88% |
| 2023 Q3 | -18.17 Thousand USD | -26.62% |
| 2023 FY | - USD | 81.39% |
| 2022 Q3 | 13.19 Thousand USD | -43.37% |
| 2022 FY | - USD | -368.77% |
| 2022 Q1 | -60.39 Thousand USD | -540.16% |
| 2022 Q2 | 23.29 Thousand USD | 138.57% |
| 2022 Q4 | -88.24 Thousand USD | -768.99% |
| 2021 Q2 | -53.54 Thousand USD | 0.0% |
| 2021 FY | - USD | -169.06% |
| 2021 Q4 | 13.72 Thousand USD | -81.84% |
| 2021 Q3 | 75.54 Thousand USD | 241.09% |
| 2020 FY | - USD | -50.46% |
| 2019 FY | - USD | 24.45% |
| 2018 FY | - USD | 2.99% |
| 2017 FY | - USD | -56.47% |
| 2016 FY | - USD | -48.47% |
| 2015 FY | - USD | 708.01% |
| 2014 FY | - USD | 0.0% |
| 1997 Q2 | -411 Thousand USD | -237.0% |
| 1997 Q3 | -172 Thousand USD | 58.15% |
| 1997 Q1 | 300 Thousand USD | 160.0% |
| 1996 Q3 | -357 Thousand USD | 20.0% |
| 1996 Q4 | -500 Thousand USD | -25.0% |
| 1996 Q1 | -600 Thousand USD | 84.21% |
| 1996 Q2 | -473 Thousand USD | 16.67% |
| 1996 FY | - USD | 36.67% |
| 1995 Q2 | 200 Thousand USD | -33.33% |
| 1995 FY | - USD | 33.33% |
| 1995 Q4 | -3.8 Million USD | -1366.67% |
| 1995 Q3 | 300 Thousand USD | 50.0% |
| 1995 Q1 | 300 Thousand USD | 123.08% |
| 1994 Q4 | -1.3 Million USD | -18.18% |
| 1994 Q1 | -900 Thousand USD | 30.77% |
| 1994 Q2 | -1 Million USD | -11.11% |
| 1994 Q3 | -1.1 Million USD | -10.0% |
| 1994 FY | - USD | -36.36% |
| 1993 Q1 | -600 Thousand USD | 45.45% |
| 1993 Q3 | -500 Thousand USD | 55.56% |
| 1993 Q4 | -1.3 Million USD | -225.0% |
| 1993 FY | - USD | 37.74% |
| 1993 Q2 | -900 Thousand USD | -50.0% |
| 1992 Q2 | -1.5 Million USD | -950.0% |
| 1992 FY | - USD | -65.63% |
| 1992 Q4 | -1.3 Million USD | 26.67% |
| 1992 Q3 | -1.5 Million USD | 11.76% |
| 1992 Q1 | 200 Thousand USD | 133.33% |
| 1991 Q3 | -400 Thousand USD | 50.0% |
| 1991 FY | - USD | -1700.0% |
| 1991 Q4 | -600 Thousand USD | -50.0% |
| 1991 Q2 | -800 Thousand USD | -366.67% |
| 1991 Q1 | 300 Thousand USD | 0.0% |
| 1990 Q2 | -500 Thousand USD | -600.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1990 Q3 | 300 Thousand USD | 160.0% |
| 1990 Q4 | 300 Thousand USD | 0.0% |
| 1989 Q3 | 100 Thousand USD | 0.0% |
| 1989 Q4 | 100 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 100.574% |
| Arrayit Corporation | -3.07 Million USD | 100.217% |
| Atlantic International Corp. | -5.38 Million USD | 100.124% |
| Biocept, Inc. | -30.24 Million USD | 100.022% |
| Bioqual, Inc. | 3.03 Million USD | 99.78% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 100.882% |
| DermTech, Inc. | -97.89 Million USD | 100.007% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 100.0% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 100.033% |
| iMD Companies, Inc. | -154.65 Thousand USD | 104.319% |
| IDenta Corp. | 71.58 Thousand USD | 90.669% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 99.826% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 82.735% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 100.123% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 155.052% |
| Medical Imaging Corp. | -896.74 Thousand USD | 100.745% |
| NovelStem International Corp. | -3.78 Million USD | 100.176% |
| Optigenex Inc. | -1.18 Million USD | 100.563% |
| PharmChem, Inc. | 1.05 Million USD | 99.366% |
| Proteome Sciences plc | -1.13 Million USD | 100.588% |
| Response Genetics, Inc | -19.66 Million USD | 100.034% |
| Rennova Health, Inc. | -234.81 Thousand USD | 102.845% |
| RushNet, Inc. | -614.85 Thousand USD | 101.086% |
| ScreenPro Security Inc. | -3.43 Million USD | 100.194% |
| Stella Diagnostics Inc. | -5.7 Million USD | 100.117% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 100.065% |
| Todos Medical Ltd. | -9.39 Million USD | 100.071% |